MeSH D019148 - neuromuscular blockade
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| AOP Health | Sugammadex | Sugammadex Amomed | 2023-01-10 | |||
| Fresenius Kabi | Sugammadex | Sugammadex Fresenius Kabi | 2022-07-15 | |||
| Merck & Co | Sugammadex | Bridion | 2008-07-25 | $1,796 M | Q2/23-Q1/24 | |
| Mylan | Sugammadex | Sugammadex Mylan | 2021-11-15 | |||
| Piramal Critical Care | Sugammadex | Sugammadex Piramal | 2023-06-23 |
Clinical Trials
Historical Success Rate
Phase 1
100%2/2
Phase 2
89%8/9
Phase 3
100%8/8
Approved: 1Overall Success rate: 89%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use